Oct. 22 at 3:18 PM
$CTSO so, according to the Company’s Q2 2025 report, CTSO had approximately
$10.2 million in unrestricted cash and
$1.5 million in restricted cash. Those balances appear insufficient to continue funding operations through 2026. Furthermore, with the govt shutdown, it is questionable whether a resubmission and approval of DrugSorb-ATR will occur sometime in 2026. And, even if it is eventually approved, the Company currently lacks the resources to roll-out their products in North America using a direct sales force. I don’t see them doing an equity offering with the share price currently hovering around $.85./ share. Will they do a reverse split and dilute existing shareholders or attempt some non-dilutive alternative to protect existing shareholders? I think it’ll be a reverse split before the beginning of Q2 2026. What say you?
